Features of course and treatment of chronic heart failure in patients with diabetes mellitus type 2
Vol 86 No 1 (2020), Therapy
Vol 86 No 1 (2020)

Features of course and treatment of chronic heart failure in patients with diabetes mellitus type 2

Therapy
https://doi.org/10.35339/msz.2020.86.01.03
Published March 31, 2020
Yu.G. Gorb
L.T. Malaya Therapy National Institute of the NAMS of Ukraine, Kharkiv, Ukraine
https://orcid.org/0000-0002-9352-5871
V.I. Strona
L.T. Malaya Therapy National Institute of the NAMS of Ukraine, Kharkiv, Ukraine
https://orcid.org/0000-0002-7483-0248
O.V. Tkachenko
L.T. Malaya Therapy National Institute of the NAMS of Ukraine, Kharkiv, Ukraine
https://orcid.org/0000-0002-6042-5559
V.V. Ryabukha
L.T. Malaya Therapy National Institute of the NAMS of Ukraine, Kharkiv, Ukraine
https://orcid.org/0000-0002-1850-1845
PDF (Українська)

Keywords

chronic heart failure
diabetes mellitus type 2
course
prognosis
treatment

How to Cite

Gorb, Y., Strona, V., Tkachenko, O., & Ryabukha, V. (2020). Features of course and treatment of chronic heart failure in patients with diabetes mellitus type 2. Medicine Today and Tomorrow, 86(1), 17-32. https://doi.org/10.35339/msz.2020.86.01.03
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

The epidemiology of chronic heart failure in patients with diabetes mellitus type 2, their general pathophysiological mechanisms, the influence of diabetes mellitus type 2 on the course and prognosis of chronic heart failure are considered. The high prevalence of chronic heart failure of all phenotypes among patients with diabetes mellitus type 2 and the increased risk of developing diabetes mellitus type 2 in patients with chronic heart failure confirm the close relationship and the high degree of comorbidity between these pathological conditions. It is shown that the development and progression of chronic heart failure in patients with diabetes mellitus type 2 is the formation of diabetic cardiomyopathy, which is characterized by disorders of energy metabolism of cardiomyocytes, mitochondrial dysfunction with subsequent apoptosis and myocardial fibrosis. Important links in the pathogenesis of chronic heart failure in diabetes mellitus type 2 are also the accession of diabetic cardiovascular autonomic neuropathy, activation of the renin-angiotensin-aldosterone system, endothelial dysfunction, exposure to atherogenic factors, arterial hypertension, obesity. The features of treatment of chronic heart failure in patients with diabetes mellitus type 2, the results of randomized clinical studies, the choice of target glycemic levels, the effectiveness of different groups of antihyperglycemic agents, drugs for the treatment of chronic heart failure, as well as their impact on the course and prognosis of chronic heart failure.

Keywords: chronic heart failure, diabetes mellitus type 2, course, prognosis, treatment.

https://doi.org/10.35339/msz.2020.86.01.03
PDF (Українська)

References

American Diabetes Association. (2020). 1. Standards of Medical Care in Diabetes - 2020. Diabetes Care, 43(1), 7-13. DOI: 10.2337/dc20-S001. PMID: 31862744.

American Diabetes Association. (2020). 10. Cardiovascular disease and risk management: standards of medical care in diabetes - 2020. Diabetes Care, 43(1), 111-134. DOI: 10.2337/dc20-S010. PMID: 31862753.

Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., et al. (2019). Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 АСС/АНА/ HFSA heart failure guideline update. Circulation, 140(7), 294-324. DOI: 10.1161/ CIR.0000000000000691. PMID: 31167558.

Rezende, P. C., Hlatky, M. A., Hueb, W., Garcia, R. M.R., da Silva Selistre, L., Lima, E. G. et al. (2020). Association of longitudinal values of glycated hemoglobin with cardiovascular events in patients with type 2 diabetes and multivessel coronary artery disease. JAMA Netw. Open., 3(1), eІ919666. DOI: 10.1001/jamanetworkopen.2019.19666. PMID: 31968117. PMCID: PMC6991270.

Sardu, C., De Lucia, C., Wallner, M., Santull, G. (2019). Diabetes mellitus and its cardiovascular complications: new insights into an old disease. J. of Diabetes Research, 2019, article ID 1905194. DOI: 10.1155/2019/1905194. PMID: 31236416. PMCID: PMC6545772.

Mitchell, S.,Malanday, B., Damascene, A., Eckel, R.H., Gaita, D., Kotseva, K. et al. (2019). A roadmap on the prevention of cardiovascular disease among people living with diabetes. Glob. Heart., 14(3), 215-240. DOI: 10.1016/j.gheart.2019.07.009. PMID: 31451236.

Elder, D. H., Singh, J. S., Levin, D., Donnelly, L. A., Choy, A. M., George, J. et al. (2016). Mean HbAlc and mortality in diabetic individuals with heart failure: a population cohort study. Eur. J. Heart Fail., 18(1), 94-102. DOI: 10.1002/ejhf.455. PMID: 26663216.

Korobka, O. (2020). Nastanovy shchodo vedennia patsiientiv iz tsukrovym diabetom ta sertsevoiu nedostatnistiu [Guidelines for the management of patients with diabetes mellitus and heart failure], Zdorovia Ukrainy - Health of Ukraine, 1, 23 [in Ukrainian].

Nechyporuk, N. (2019). Tsukrovyi diabet 2-ho typu ta sertseva nedostatnist: naukove sudzhennia vid Amerykanskoi asotsiatsii sertsia ta Amerykanskoho tovarystva sertsevoi nedostatnosti [Type 2 diabetes and heart failure: a scientific judgment from the American Heart Association and the American Heart Failure Society], Zdorovia Ukrainy - Health of Ukraine, 4, 23-25 [in Ukrainian].

Boonman-de Winter, L. J., Rutten, F. H., Cramer, M. J., Landman, M. J., Liem, A. H., Rutten, G. E. et al. (2012). High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia, 55(8), 2154—2162. DOI: 10.1007/s00125-012-2579-0. PMID: 22618812. PMCID: PMC3390708.

Echouffo-Tcheugui, J. B., Xu, H., DeVore, A. D., Schulte, P. J., Butler, J., Yancy, C. W. et al. (2016).Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from get with the guidelines-heart failure registry. Am. Heart J., 182, 9-20. DOI: 10.1016/j.ahj.2016.07.02. PMID: 27914505.

Iwakura, K. (2019). Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments. J. Echocardiogr, 17(4), 177-186. DOI: 10.1007/sl2574-019-00446-9. PMID: 31617144.

Musaeus, K. D., Pareek M. (2018). Body mass index, type 2 diabetes, and left ventricular function. Cardiovasc. Diabetol., 17(1), 3. DOI: 10.1186/sl2933-017-0649-9. PMID: 29301532. PMCID: PMC5753471.

Johansson, L, Dahlstrom, U., Edner, M., Nasman, P., Ryden, L., Norhammar, A. (2016). Prognostic implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure. J. Am. Coll. Cardiol., 68(13), 1404-1416. DOI: 10.1016/j.jacc.2016.06.061. PMID: 27659462.

Basu, S., Raghavan, S., Wexler, D.J., Berkowitz, S.A. (2018). Characteristics associated with decreased or increased mortality risk from glycemic therapy among patients with type 2 diabetes and high cardiovascular risk: machine learning analysis of the ACCORD Trial. Diabetes Care, 41(3), 604-612. DOI: 10.2337/dcl7-2252. PMID: 29279299. PMCID: PMC5829969.

Pandey, A., Patel, K. V., Bahnson, J. L., Gaussoin, S. A., Martin, C. K., Balasubramanyam, A. et al. (2020). Association of intensive lifestyle intervention, fitness and body mass index with risk of heart failure in overweight or obese adults with type 2 diabetes mellitus: an analysis from the Look AHEAD Trial. Circulation, 141(16), 1295-1306. DOI: 10.1161/CIRCULATIONAHA. 119.044865. PMID: 32134326.

Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., et al. (2020). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur. Heart J., 41(2), 255-323. DOI: 10.1093/eurheartj/ehz486. PMID: 31497854.

Sandesara, P. B., O’Neal, W. T., Kelli, H. M., Samman-Tahhan, A., Hammadah, M., Quyyumi, A. A. et al. (2018). The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction. Diabetes Care, 41(l), 150-155. DOI: 10.2337/ dcl7-0755. PMID: 29051160. PMCID: PMC5741155.

Voronkov, L. H. (2019). Personifikovane likuvanniakhronichnoi sertsevoinedostatnosti [Personalized treatment of chronic heart failure], Zdorovia Ukrainy - Health of Ukraine, 5, 35 [in Ukrainian].

Dutka, R. Ya., Chmir, N. V. (2018). Patohenetychna ta klinichna sporidnenist perebihu tsukrovoho diabetu 2-ho typu z metabolichnym syndromom ta khronichnoiu ishemichnoiu khvoroboiu sertsia [Pathogenetic and clinical relationship of type 2 diabetes mellitus with metabolic syndrome and chronic coronary heart disease], Mizhnarodnyi endokrynolohichnyi zhurnal—International Journal of Endocrinology, 14(7), 655-660. DOI: 10.22141/2224-0721.14.7.2018.148772.

Targher, G., Byrne, C. D. (2020). Treatment algorithm in patients with type 2 diabetes and atherosclerotic cardiovascular disease or high/very high cardiovascular risk. Eur. Heart J., 41(2), 331. DOI: 10.1093/eurheartj/ehz831, РМID: 31800051.

Korobka, O. (2020). Rekomendatsii shchodo likuvannia і profilaktyky tsukrovoho diabetu, prediabetu ta sertsevo-sudynnykh zaklivoriuvan [Recommendations for the treatment and prevention of diabetes, prediabetes and cardiovascular disease], Zdorovia Ukrainy — Health of Ukraine, 1, 15-16 [in Ukrainian].

Liang, B., Zhao, Y, Gu, N. (2020). Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions. Cardiovasc. Diabetol., 19, 29. DOI: 10.1186/S12933-020-01004-9. PMID: 32156272. PMCID: PMC7063753.

Tripolt, N.J., Kolesnik, E. Pferschy, P. N., Verheyen, N., Ablasser, K., Sailer, S., et al. (2020). Impact of empagliflozin on cardiac function and biomarkers of heart failure in patients with acute myocardial infarction -The EMMY trial. Am. Heart J., 22(l), 39-47. DOI: 10.1016/j.ahj.2019.12.004. PMID: 31901799.

Otagaki, M., Matsumura, K., Kin, H., Fujii, K., Shibutani, H., Matsumoto, H., et al. (2019). Effect of tofogliflozin on systolic and diastolic cardiac function in type 2 diabetic patients. Cardiovasc. Drugs Then, 33(4), 435-442. DOI: 10.1007/sl0557-019-06892-y. PMID: 31321581.

Zelniker, T. A., Bonaca, M. R., Furtado, R. H. M., Mosenzon, O., Kuder, J. F., Murphy, S. A., et al. (2020). Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus. Circulation, 141(15), 1227-1234. DOI: 10.1161/CIRCULATIONAHA. 119.044183. PMID: 31983236.

Inzucchi, V. E., Kliunti, K., Fitchett, D., Wanner, C., Mattheus, M., George, J., et al. (2019). 19-LB: Consistent cardiovascular (CV) benefits from empagliflozin across the spectrum of CV risk factor control: post hoc analysis from EMPA-REG OUTCOME. Diabetes, 68(1). DOI: 10.2337/dbl9-19-LB.

Neal, B., Perkovic, V, Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N. et al. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med., 377(7), 644-657. DOI: 10.1056/NEJMoal611925. PMID: 28605608.

Kosiborod, M., Lam, C. S. P., Kohsaka, S., Kim, D. J., Karasik, A., Shaw, J., et al. (2018). Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 Study. J. Am. Coll. Cardiol., 71(23), 2628-2639. DOI: 10.1016/j.jacc.2018.03.009. PMID: 29540325.

Connelly, К. А., Zhang, Y., Desjardins, J., Nghiem, L., Visram, A., Batchu, S. N., et al. (2020). Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovasc. Diabetol., 19(1), 13. DOI: 10.1186/sl2933-020-0994-y. PMID: 32035482. PMCID: PMC7007658.

Jorsal, A., Persson, F., Bruun, J. M. (2020). Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur. Heart J., 41(2), 328. DOI: 10.1093/eurheartj/ ehz777. PMID: 31803914.

Kosiborod, M., Nassif, M., Windsor, S., Tang, F., Khariton, Y., Austin, B., et al. (2019). Effects of dapagliflozin on biomarkers, symptoms and functional status in patients with heart failure with reduced ejection fraction with and without diabetes - The Define-HF Trial. J. Card. Fail., 25(11), 937-938. DOI: 10.1016/j.cardfail.2019.ll.005 .

Zheng, S. L., Roddick, A. J., Aghar-Jaffar, R., Shun-Shin, M. J., Francis, D., Oliver, N., et al. (2018). Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA, 319(15), 1580-1591. DOI: 10.1001/jama.2018.3024. PMID: 29677303. PMCID: PMC5933330.

Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med., 380(4), 347-357. DOI: 10.1056/NEJMoal812389. PMID: 30415602.

Kaplinsky, E. (2019). DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. Drugs Context., 9. DOI: 10.7573/dic.2019-ll-3. PMID: 32165892. PMCID: PMC7051244.

Romaniuk, S. (2020). Onovlennia v likuvanni sertsevoi nedostatnosti [Updates in the treatment of heart failure], Zdorovia Ukrainy — Health of Ukraine, 1, 24-25 [in Ukrainian].

Kenny, H. C., Abel, E. D. (2019). Heart failure in type 2 diabetes mellitus: impact of glucose lowering agents, heart failure therapies and novel therapeutic strategies. Circ. Res., 124(1), 121-141. DOI: 10.1161/CIRCRESAHA.118.311371. PMID: 30605420. PMCID: PMC6447311, NIHMSID: NIHMS1514421.

Strilchuk, L. (2019). Zastosuvannia suchasnykh tsukroznyzhuvalnykh preparativ і zmenshennia sertsevo-sudynnoho ryzyku v patsiientiv iz TsD 2 typu [The use of modern antidiabetic drugs and reducing cardiovascular risk in patients with type 2 diabetes], Zdorovia Ukrainy - Health of Ukraine, 19, 16 [in Ukrainian].

Zak, K. P., Furmanova, O. V. (2018). Immunnyie і protivovospalitelnyie faktory v mekhanizme lechebnoho deistviia metformina. Mizhnarodnyi endokrynolohichnyi zhurnal — International Journal of Endocrinology, 14, 2, 90-97. DOI: 616.379-008.64-08:612.017.l.

Skelin, M., Lucijanic, M., Javor, E. (2020). The possible role of insulin and glucagon in patients with heart failure and type 2 diabetes. Eur. Heart J., 41(2), 325. DOI: 10.1093/eurheartj/ ehz242. PMID: 31323668.

Solis-Herrera, C., Sheikh, O., Chilton, R. (2020). A new perspective on lowering CV risk from hypoglycaemia. Eur. Heart J., 41(2), 218-220. DOI: 10.1093/eurheartj/ehz730. PMID: 31605128.

Koroliuk, O. (2019). Vedennia patsiientiv iz SN (Referatyvnyi ohliad yevropeiskykh nastanov 2019 roku shchodo vedennia diabetu, prediabetu ta sertsevo-sudynnykh zakhvoriuvan) [Management of patients with HF (Abstract review of European guidelines for 2019 on the management of diabetes, prediabetes and cardiovascular disease)]. Zdorovia Ukrainy - Health of Ukraine, 19, 18-20 [in Ukrainian].

Lepore, J. J., Olson, E., Demopoulos, L., Haws, T., Fang, Z., Barbour, A. M., et al. (2016). Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail., 4(7), 559-566. DOI: 10.1016/j.jchf.2016.01.008. PMID: 27039125.

Liu, F., Kong, Y. (2020). GLP-1 receptor agonist on cardiovascular complications of diabetes mellitus. Exp. Then Med., 19(3), 2259-2265. DOI: 10.3892/etm.2020.8439. PMID: 32104292. PMCID: PMC7027309.

McGuire, D. K., Van de Werf, F., Armstrong, P. W., Standi, E., Koglin, J., Green, J. B., et al. (2016). Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol., 1(2), 126-135. DOI: 10.1001/jamacardio.2016.0103. PMID: 27437883.

Pankiv, V. I. (2019). Mozhlyvosti vildahliptynu v optymalnomu kontroli tsukrovoho diabetu 2-ho typu [Possibilities of vildagliptin in optimal control of type 2 diabetes], Mizhnarodnyi endokiynolohichnyi zhurnal - International Journal of Endocrinology, 15(6), 482-487. DOI: 10.22141/2224-0721.15.6.2019.185411.

Tanaka, H., Soga, F., Tatsumi, K., Mochizuki, Y., Sano, H., Toki, H., et al. (2020). Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. Cardiovasc. Diabetol., 19(1), 6. DOI: 10.1186/sl2933-019-0985-z. PMID: 31910853. PMCID: PMC6947966.

Voronkov, L. H. (2018). IAPF pri serdechno-sosudistoi patolohii: ramipril как dokazatelnaia model [ACE inhibitors in cardiovascular disease: ramipril as an evidence-based model], Sertseva nedostatnist ta komorbidni stany — Heart failure and comorbid conditions, 1, 25—30 [in Russian].

Januzzi, J. L., Prescott, M. F., Butler, J., Felker, M., Maisel, A. S., Pina, I., et al. (2019). Effects of angiotensin receptor/neprilysin inhibitor therapy on amino-terminal pro-B-type natriuretic peptide and cardiac remodeling in heart failure with reduced ejection fraction: The PROVE-HF Study. J. Card. Fail., 25(11), 937. DOI: 10.1016/j.cardfail.2019.ll.004.

Sidorova, L. L. (2018). Blokatory P-adrenoretseptorov pri zabolevaniiakh serdechno-sosudistoi sistemy і sakhamom diabete: gap in knowledge? [P-adrenergic receptor blockers in diseases of the cardiovascular system and diabetes mellitus: gap in knowledge?]. Ukrainskyi medychnyi chasopys — Ukrainian Medical Journal, 1, 3, 2-5 [in Russian].

Cosentino F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., et al. (2020). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J, 41(2), 255-323. DOI: 10.1093/eurheartj/ehz486. PMID: 31497854.

Luscher, T. F. (2020). A revolution in diabetes care: novel drugs and new recommendations. Eur. Heart J., 41(2), 195-198. DOI: 10.1093/eurheartj/ehz966. PMID: 33216913.